Cancer Blood Tests Part 2: The clinical trial
Summary
Hosts Kristen Sinani and Regina Nuzzo analyze the controversial NHS Galleri trial, revealing that the primary endpoint for reducing advanced cancers was missed. They scrutinize secondary data, noting statistical issues like post-hoc adjustments and suspicious exclusions that favor the test. Despite some significant findings in early-stage detection, the hosts conclude the evidence remains inconclusive and potentially misleading.
Topics discussed
Introduction to the Gallerie multi-cancer early detection test
Overview of the NHS Gallerie randomized trial design
Primary outcome: Stage 3 and 4 cancer diagnosis rates
Secondary outcomes and post-hoc analysis concerns
Controversial headlines and stock market reaction
Analysis of screening rounds and prevalent vs. incident cases
Statistical sleuthing: Excluded cancers and data inconsistencies
Focus on Stage 4 cancers and missing data issues
Early-stage detection benefits and test performance metrics
Final verdict: Is the test ready for prime time?
Listen ad-free on Castria